Harini Krishnan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7317403/publications.pdf

Version: 2024-02-01

759055 940416 20 820 12 16 citations h-index g-index papers 21 21 21 1483 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Heterocellular N-cadherin junctions enable nontransformed cells to inhibit the growth of adjacent transformed cells. Cell Communication and Signaling, 2022, 20, 19.	2.7	1
2	Independent effects of Src kinase and podoplanin on anchorage independent cell growth and migration. Molecular Carcinogenesis, 2022, , .	1.3	1
3	Evidence that Maackia amurensis seed lectin (MASL) exerts pleiotropic actions on oral squamous cells with potential to inhibit SARS-CoV-2 infection and COVID-19 disease progression. Experimental Cell Research, 2021, 403, 112594.	1.2	15
4	Src and podoplanin forge a path to destruction. Drug Discovery Today, 2019, 24, 241-249.	3.2	30
5	Podoplanin: An emerging cancer biomarker and therapeutic target. Cancer Science, 2018, 109, 1292-1299.	1.7	134
6	Abstract 968: Podoplanin's diverse potential as a chemotherapeutic target for oral squamous cell carcinom., 2017,,.		0
7	Abstract 1215: Utilization of podoplanin as a chemotherapeutic target for oral squamous cell carcinoma. Cancer Research, 2016, 76, 1215-1215.	0.4	1
8	PKA and CDK5 can phosphorylate specific serines on the intracellular domain of podoplanin (PDPN) to inhibit cell motility. Experimental Cell Research, 2015, 335, 115-122.	1.2	21
9	Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. Carcinogenesis, 2015, 36, S254-S296.	1.3	239
10	Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression. Carcinogenesis, 2015, 36, S2-S18.	1.3	55
11	Podoplanin. Journal of Neuropathology and Experimental Neurology, 2015, 74, 64-74.	0.9	41
12	Contact Normalization or Escape from the Matrix. , 2015, , 297-342.		4
13	Abstract 4375: Podoplanin (PDPN): novel biomarker and chemotherapeutic target. , 2015, , .		13
14	Antibody and lectin target podoplanin to inhibit oral squamous carcinoma cell migration and viability by distinct mechanisms. Oncotarget, 2015, 6, 9045-9060.	0.8	77
15	Serines in the Intracellular Tail of Podoplanin (PDPN) Regulate Cell Motility. Journal of Biological Chemistry, 2013, 288, 12215-12221.	1.6	63
16	Src Points the Way to Biomarkers and Chemotherapeutic Targets. Genes and Cancer, 2012, 3, 426-435.	0.6	18
17	Plant Lectin Can Target Receptors Containing Sialic Acid, Exemplified by Podoplanin, to Inhibit Transformed Cell Growth and Migration. PLoS ONE, 2012, 7, e41845.	1.1	61
18	Chapter 6. Contact Normalization: Mechanisms and Pathways to Biomarkers and Chemotherapeutic Targets. RSC Drug Discovery Series, 2011, , 105-115.	0.2	3

#	Article	IF	CITATION
19	Src activates Abl to augment Robo1 expression in order to promote tumor cell migration. Oncotarget, 2010, 1, 198-209.	0.8	25
20	Src activates Abl to augment Robo1 expression in order to promote tumor cell migration. Oncotarget, 2010, 1, 198-209.	0.8	17